(CE) Celanese - NYSE
Sector: Basic Materials | Industry: Chemicals | Exchange: NYSE (USA) | Market Cap: 5.454m USD | Total Return: -12.4% in 12m
Avg Turnover: 74.9M
EPS Trend: -87.7%
Qual. Beats: 0
Rev. Trend: -88.3%
Qual. Beats: 0
Warnings
High Debt/EBITDA (27.4) with thin interest coverage (-0.5)
Interest Coverage Ratio -0.5 is critical
Below Avwap Earnings
Tailwinds
Confidence
Celanese Corporation is a global producer and seller of engineered polymers, operating through two segments: Engineered Materials and Acetyl Chain. The Engineered Materials segment supplies high-performance polymers and thermoplastics (such as polyoxymethylene, nylon compounds, liquid crystal polymers, and thermoplastic elastomers) used across automotive, consumer electronics, medical, construction, energy storage, and industrial applications. The Acetyl Chain segment provides acetyl-based products-including acetic acid, vinyl acetate monomers, acetate tows, and emulsions-that serve as building blocks for adhesives, coatings, flexible packaging, paints, textiles, and pharmaceutical applications. The company sells under a broad portfolio of brands (including Hostaform, Celanex, Santoprene, Hytrel, and Zytel) via direct sales, distributors, and OEMs, and was founded in 1912 with headquarters in Irving, Texas.
As a specialty chemicals company within the Materials sector, Celanese occupies a vertically integrated position in the acetyl value chain, converting basic feedstocks like ethylene and methanol into higher-margin intermediates and downstream polymers. Its dual-segment model pairs commodity-scale acetyl production with differentiated engineered materials, allowing the business to serve both volume-driven industrial customers and performance-driven specialty end markets.
- Acetyl chain margins pressured by weak acetic acid pricing
- Engineered Materials demand softens on automotive destocking
- Deleveraging from M&M acquisition remains key investor focus
| Net Income: -1.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.88 > 1.0 |
| NWC/Revenue: 17.41% < 20% (prev 26.06%; Δ -8.64% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.19b > Net Income -1.09b |
| Net Debt (11.1b) to EBITDA (407.0m): 27.39 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.0m) vs 12m ago 0.55% < -2% |
| Gross Margin: 19.83% > 18% (prev 22.65%; Δ -2.82% > 0.5%) |
| Asset Turnover: 42.25% > 50% (prev 43.36%; Δ -1.11% > 0%) |
| Interest Coverage Ratio: -0.50 > 6 (EBIT TTM -379.0m / Interest Expense TTM 751.0m) |
| A: 0.08 (Total Current Assets 5.97b - Total Current Liabilities 4.32b) / Total Assets 21.7b |
| B: 0.46 (Retained Earnings 9.92b / Total Assets 21.7b) |
| C: -0.02 (EBIT TTM -379.0m / Avg Total Assets 22.5b) |
| D: 0.24 (Book Value of Equity 4.06b / Total Liabilities 17.2b) |
| Altman-Z'' = 2.12 = BBB |
| DSRI: 1.44 (Receivables 1.68b/1.24b, Revenue 9.49b/10.1b) |
| GMI: 1.14 (GM 22.65% / 19.83%) |
| AQI: 0.95 (AQ_t 0.50 / AQ_t-1 0.52) |
| SGI: 0.94 (Revenue 9.49b / 10.1b) |
| TATA: -0.10 (NI -1.09b - CFO 1.19b) / TA 21.7b) |
| Beneish M = -2.62 (Cap -4..+1) = A |
As of June 27, 2026, the stock is trading at USD 49.42 with a total of 3,254,318 shares traded. Over the past week, the price has changed by -3.40%, over one month by -5.63%, over three months by -19.66% and over the past year by -12.41%.
Current recommended Stop Loss: 46.20 (which is 6.5% or 1.4 ATR below the current price).
Celanese has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CE.
- StrongBuy: 8
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 74.6 | 50.9% |
P/E Forward = 8.4388
P/S = 0.5745
P/B = 1.3808
P/EG = 4.4198
Revenue TTM = 9.49b USD
EBIT TTM = -379.0m USD
EBITDA TTM = 407.0m USD
Long Term Debt = 10.8b USD (from longTermDebt, last quarter)
Short Term Debt = 1.74b USD (from shortTermDebt, last quarter)
Debt = 12.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 351.0m
Net Debt = 11.1b USD (calculated: Debt 12.9b - CCE 1.76b)
Enterprise Value = 16.6b USD (5.45b + Debt 12.9b - CCE 1.76b)
Interest Coverage Ratio = -0.50 (Ebit TTM -379.0m / Interest Expense TTM 751.0m)
EV/FCF = 18.91x (Enterprise Value 16.6b / FCF TTM 878.0m)
FCF Yield = 5.29% (FCF TTM 878.0m / Enterprise Value 16.6b)
FCF Margin = 9.25% (FCF TTM 878.0m / Revenue TTM 9.49b)
Net Margin = -11.54% (Net Income TTM -1.09b / Revenue TTM 9.49b)
Gross Margin = 19.83% ((Revenue TTM 9.49b - Cost of Revenue TTM 7.61b) / Revenue TTM)
Gross Margin QoQ = 18.96% (prev 17.38%)
Tobins Q-Ratio = 0.76 (Enterprise Value 16.6b / Total Assets 21.7b)
Interest Expense / Debt = 5.82% (Interest Expense 751.0m / Debt 12.9b)
Taxrate = 40.24% (33.0m / 82.0m)
NOPAT = -226.5m (EBIT -379.0m * (1 - 40.24%)) [loss with tax shield]
Current Ratio = 1.38 (Total Current Assets 5.97b / Total Current Liabilities 4.32b)
Debt / Equity = 3.18 (Debt 12.9b / totalStockholderEquity, last quarter 4.06b)
Debt / EBITDA = 27.39 (Net Debt 11.1b / EBITDA 407.0m)
Debt / FCF = 12.70 (Net Debt 11.1b / FCF TTM 878.0m)
Total Stockholder Equity = 4.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.87% (Net Income -1.09b / Total Assets 21.7b)
RoE = -25.26% (Net Income TTM -1.09b / Total Stockholder Equity 4.34b)
RoCE = -2.50% (EBIT -379.0m / Capital Employed (Equity 4.34b + L.T.Debt 10.8b))
RoIC = -1.21% (negative operating profit) (NOPAT -226.5m / Invested Capital 18.7b)
WACC = 5.32% (E(5.45b)/V(18.4b) * Re(9.69%) + D(12.9b)/V(18.4b) * Rd(5.82%) * (1-Tc(0.40)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.94 | Cagr: 0.20%
[DCF] Terminal Value 77.97% ; FCFF base≈727.6m ; Y1≈834.1m ; Y5≈1.23b
[DCF] Fair Price = 66.80 (EV 18.5b - Net Debt 11.1b = Equity 7.33b / Shares 109.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -87.75 | EPS CAGR: -26.84% | SUE: -0.13 | # QB: 0
Revenue Correlation: -88.26 | Revenue CAGR: -4.52% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.24 | Chg30d=+0.00% | Revisions=+67% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.84 | Chg30d=+0.00% | Revisions=+44% | Analysts=15
EPS current Year (2026-12-31): EPS=6.14 | Chg30d=+0.00% | Revisions=+67% | GrowthEPS=+54.2% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=6.63 | Chg30d=+0.00% | Revisions=+38% | GrowthEPS=+8.0% | GrowthRev=+0.8%
[Analyst] Revisions Ratio: +67%